2025年11月13日,诺诚健华(688428.SH,09969.HK)发布2025年三季报,整体营业收入再创新高,经营质量持续提升。奥布替尼前三季度突破去年全年收入 2025年全年预计实现盈亏平衡诺诚健华2025年前三季度总收入同比增长59.8%,达到11.2亿元,主要是因为核心产品BTK抑制剂奥布替尼(宜诺凯)销售收入的持续增长以及公司和Prolium达成授权许可获得的首付款。奥布替尼前三季度...
Source Link2025年11月13日,诺诚健华(688428.SH,09969.HK)发布2025年三季报,整体营业收入再创新高,经营质量持续提升。奥布替尼前三季度突破去年全年收入 2025年全年预计实现盈亏平衡诺诚健华2025年前三季度总收入同比增长59.8%,达到11.2亿元,主要是因为核心产品BTK抑制剂奥布替尼(宜诺凯)销售收入的持续增长以及公司和Prolium达成授权许可获得的首付款。奥布替尼前三季度...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.